Zydus Lifesciences Limited
Momentum (90/100) does the heavy lifting; financial trend (57/100) is the drag.
Buy zoneZydus Lifesciences Limited earns a Strong Buy from StocksWizard, with a blended score of 75/100. At ₹1,126.8 it trades below our blended DCF and relative-multiples fair value of ₹1,705.4, about 51% upside to that estimate — we read it as undervalued by 51%. On 22.0x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹1,157.96. Financial health scores 79/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. The average analyst target of ₹1,066.5 implies about 5% downside across 30 analysts. It clears 11 of 13 investability checks, with durability 65, valuation 73 and momentum 90 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,364.32.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-2.69% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy75Piotroski F-score 2/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 18.3%
- Pass: Low debt (D/E < 0.5): 0.42x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 16%
- Pass: Earnings growing: 9%
- Pass: Net margin ≥ 10%: 18.6%
- Fail: Current ratio > 1.5: 1.27
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.15
- Fail: Piotroski ≥ 7: 2/9
Quarterly results
Annual financials
Shareholding
- Promoter75.8%
- Institutions15.1%
- Public & other9.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (18.3%).
- Healthy profit margin (18.6%).
- Trading near its 52-week high.
- Financially solid — Altman Z 4.15.
Opportunities
- Revenue growing (16% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~51% below our estimated fair value.
Bear case
Weaknesses
- Weak Piotroski score (2/9).
About Zydus Lifesciences Limited
Zydus Lifesciences develops and markets pharmaceutical products across India, the US, and internationally. Operating through Pharmaceuticals and Consumer Products segments, the company produces active pharmaceutical ingredients, finished dosage formulations, generics, specialty drugs, biosimilars, vaccines, and novel products, along with consumer wellness and animal health brands including Everyuth, Nutralite, and SugarFre.
Zydus Lifesciences Limited — frequently asked questions
Is Zydus Lifesciences Limited a buy, hold or sell?
StocksWizard currently rates Zydus Lifesciences Limited (ZYDUSLIFE) a Strong Buy, based on a blended score of 75/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Zydus Lifesciences Limited's fair value?
Our blended DCF and relative-valuation model estimates Zydus Lifesciences Limited's fair value at about ₹1,705.4, versus a current price of ₹1,126.8 — roughly 51% upside. On that basis the stock looks undervalued by 51%.
Is Zydus Lifesciences Limited financially healthy?
Zydus Lifesciences Limited scores 79/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9.
How has Zydus Lifesciences Limited's share price performed?
Zydus Lifesciences Limited is up 24% over three months, and last traded at ₹1,126.8. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.